ArticleDrugs in context2023
Effect of xyloglucan associations with gelatin or gelose on Escherichia coli-derived lipopolysaccharide-induced enteritis in rats.
Article in Drugs in context, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Mucoprotectants and gut barrier: mechanisms of action and clinical applications in IBS. Is there a possible role?Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Xyloglucan (12.5 mg/kg) plus gelatin (250 mg/kg) or gelose (250 or 500 mg/kg) were administered orally 2 hours before intraperitoneal injection with Results: LPS administration increased jejunal permeability and increased mucosal inflammation in male Wistar rats. Xyloglucan plus gelatin 250 mg/kg and xyloglucan plus gelose 500 mg/kg significantly attenuated LPS-induced jejunal hyperpermeability and myeloperoxidase activity. Conclusion: Xyloglucan, a known mucosal barrier protector, in combination with gelatin or gelose, has beneficial and comparable effects on intestinal permeability and inflammation following
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.